Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06246110 | A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC | PHASE2 | ACTIVE NOT_RECRUITING | 70 | — | — | Feb 6, 2024 | Dec 1, 2027 | May 28, 2026 | 38 | United States |
Defined AEs that occur during treatment and are deemed to be related EIK1001 or combination with SOC or due to disease progression or toxicity.
| Arm | Type | Description |
|---|---|---|
| Cohort A - Participants with non-squamous NSCLC | EXPERIMENTAL | Participants in this arm will receive EIK1001 + Standard of Care (SOC). |
| Cohort B - Participants with squamous NSCLC | EXPERIMENTAL | Participants in this arm will receive EIK1001 + Standard of Care (SOC). |
| Name | Type | Description |
|---|---|---|
| EIK1001 | DRUG | EIK1001 is a Toll like receptor 7/8 (TLR 7/8) agonist |
| Pembrolizumab | DRUG | PD-1 inhibitor |
| Paclitaxel | DRUG | Chemotherapy |
| Pemetrexed | DRUG | Chemotherapy |
| Carboplatin | DRUG | Chemotherapy |
Inclusion Criteria: 1. be ≥ 18 years of age on the day of signing of informed consent. 2. confirmed Stage 4 NSCLC (squamous or non-squamous) and be considered for standard of care. 3. have confirmation that mutation-directed therapy is not indicated (documentation of absence of tumor activating mut...